GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (OTCPK:IVBIY) » Definitions » Inventory Turnover

IVBIY (Innovent Biologics) Inventory Turnover : 0.81 (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Innovent Biologics Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Innovent Biologics's Cost of Goods Sold for the six months ended in Jun. 2024 was $93 Mil. Innovent Biologics's Average Total Inventories for the quarter that ended in Jun. 2024 was $115 Mil. Innovent Biologics's Inventory Turnover for the quarter that ended in Jun. 2024 was 0.81.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Innovent Biologics's Days Inventory for the six months ended in Jun. 2024 was 225.45.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Innovent Biologics's Inventory-to-Revenue for the quarter that ended in Jun. 2024 was 0.21.


Innovent Biologics Inventory Turnover Historical Data

The historical data trend for Innovent Biologics's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics Inventory Turnover Chart

Innovent Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventory Turnover
Get a 7-Day Free Trial 0.59 0.75 0.50 0.64 0.93

Innovent Biologics Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.33 0.31 0.36 0.56 0.81

Innovent Biologics Inventory Turnover Calculation

Innovent Biologics's Inventory Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Inventory Turnover (A: Dec. 2023 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Dec. 2023 ) / ((Total Inventories (A: Dec. 2022 ) + Total Inventories (A: Dec. 2023 )) / count )
=159.136 / ((204.955 + 135.583) / 2 )
=159.136 / 170.269
=0.93

Innovent Biologics's Inventory Turnover for the quarter that ended in Jun. 2024 is calculated as

Inventory Turnover (Q: Jun. 2024 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Jun. 2024 ) / ((Total Inventories (Q: Dec. 2023 ) + Total Inventories (Q: Jun. 2024 )) / count )
=93.394 / ((135.583 + 95.167) / 2 )
=93.394 / 115.375
=0.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innovent Biologics  (OTCPK:IVBIY) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Innovent Biologics's Days Inventory for the six months ended in Jun. 2024 is calculated as:

Days Inventory =Average Total Inventories (Q: Jun. 2024 )/Cost of Goods Sold (Q: Jun. 2024 )*Days in Period
=115.375/93.394*365 / 2
=225.45

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Innovent Biologics's Inventory to Revenue for the quarter that ended in Jun. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Jun. 2024 ) / Revenue (Q: Jun. 2024 )
=115.375 / 544.79
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.


Innovent Biologics Inventory Turnover Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovent Biologics Business Description

Traded in Other Exchanges
Address
168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.

Innovent Biologics Headlines

From GuruFocus